Speaker Profile

MD, PhD, President & CEO, Gritstone bio, Inc.

Andrew Allen, M.D., Ph.D. co-founded Gritstone bio, Inc. in 2015 and is a board member. In 2009, Dr. Allen co-founded Clovis Oncology and served as chief medical officer until 2015, driving development of rucaparib, a PARP inhibitor. Prior he was chief medical officer at Pharmion Corporation, developing Vidaza, the first DNA methylation inhibitor, until acquisition by Celgene in 2008. Dr. Allen also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey Company. He currently serves on the board of directors of TCR2 Therapeutics and Sierra Oncology (both public) and Revitope Oncology and Verge Genomics (both private). He previously served on the board of Epizyme (first approved histone methylation transferase inhibitor) and Cell Design Labs (acquired by Gilead Sciences in 2017). Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College in London.

Self-Amplifying mRNA Multi-Antigen Coronavirus Vaccine
First generation COVID-19 vaccines deliver Spike to induce protective neutralizing antibodies. Spike mutations can attenuate such narrow immunity. Gritstone bio has developed a self-amplifying mRNA vaccine platform that delivers Spike plus additional conserved T cell epitopes from other viral genes. Strong immunity has been demonstrated in NHP. Human data are being generated.

 Session Abstract – PMWC 2024 Silicon Valley

Track 1 - January 25 9.00 A.M.-4.30 P.M.

Track Chair: Sharon Benzeno, Adaptive Biotechnologies

  • PMWC 2024 Award Ceremony
    Pioneer Honoree: Stanley Riddell, Fred Hutchinson
    Pioneer Honoree: George Coukos, Ludwig Cancer Center
  • Keynote: Engineering Synthetic T Cell States for Cancer Rejection
    - George Coukos, Ludwig Cancer Center
  • Discovery of Novel Targets in Cell Therapies in Oncology and Autoimmune Disorders (PANEL)
    Chair: Harlan Robins, Adaptive Bio
    - Stanley Riddell, Fred Hutchinson
    - Allison Betof Warner, Stanford
    - Lawrence Fong, UCSF
  • Supply Chain 2.0 Getting Cell Therapies to Patients (PANEL)
    Chair: Jean Xu, Janssen Pharmaceuticals
    - Amanda Pace, Sonoma Bio
    - Laura Deschenes, Sana Biotechnology
  • Evolving Case Law and Practical Strategies for Immunotherapy Patents
    - Janet Xiao, Morrison & Foerster LLP
  • Emerging Clinical Data in Oncology Cell Therapeutics
    Chair: Andrew Allen, Gritstone bio, Inc.
    - Robert Meehan, Moderna
  • Scientific Advancements in Individualized Cell Therapies in Oncology ( PANEL)
    Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Ira Mellman, Genenetch
    - Robert Meehan, Moderna
    - Dirk Nagorsen, Affini-T Therapeutics
  • AI-Enhanced Approaches in Cell Therapy Development
    Chair: Suchit Jhunjhunwala, Genentech
    - Brian Weitzner, Outpace Bio
  • PMWC Showcase
    - Arun Wiita, UCSF


Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by JUL. 18TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required